Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 6/20 | 0.43 |
| ▸ | MMP3 | P08254 | 4/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819908 | 0.84 | FOLH1 (0.49) | — | |
| SCHEMBL4819898 | 0.84 | FOLH1 (0.49) | — | |
| SCHEMBL4904605 | 0.83 | POLB (0.44) | MMP2MMP3CTSKMEN1KMT2A | |
| SCHEMBL418665 | 0.81 | CYP3A4 (0.53) | CYP3A4TSHRMMP9CTSLCTSS | |
| SCHEMBL418578 | 0.81 | CYP3A4 (0.53) | CYP3A4TSHRMMP9CTSLCTSS | |
| SCHEMBL4897018 | 0.79 | POLB (0.46) | MMP9MMP2MMP3CTSKMEN1 | |
| SCHEMBL14104857 | 0.79 | MAPT (0.58) | MEN1KMT2A | |
| SCHEMBL4906490 | 0.77 | CTSS (0.44) | CYP3A4CTSLCTSSMEN1KMT2A | |
| SCHEMBL4814646 | 0.77 | POLB (0.50) | MMP9MMP2MMP3MEN1KMT2A | |
| SCHEMBL4814666 | 0.77 | POLB (0.50) | MMP9MMP2MMP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | CYP3A4 3318/4885TSHR 3687/4885MMP9 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.